Shandong Pharmaceutical GlassLtd Toekomstige groei

Future criteriumcontroles 1/6

Shandong Pharmaceutical GlassLtd zal naar verwachting groeien in winst en omzet met respectievelijk 18.4% en 13.6% per jaar. De winst per aandeel zal naar verwachting groeien met 18% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.2% zijn.

Belangrijke informatie

18.4%

Groei van de winst

18.0%

Groei van de winst per aandeel

Medical Equipment winstgroei	26.5%
Inkomstengroei	13.6%
Toekomstig rendement op eigen vermogen	13.2%
Dekking van analisten	Good
Laatst bijgewerkt	01 Nov 2024

Recente toekomstige groei-updates

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 26

Recent updates

Returns On Capital At Shandong Pharmaceutical GlassLtd (SHSE:600529) Have Hit The Brakes

Aug 25

Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)

May 31

The Returns At Shandong Pharmaceutical GlassLtd (SHSE:600529) Aren't Growing

May 13

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 26

Winst- en omzetgroeiprognoses

SHSE:600529 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	7,015	1,345	N/A	1,492	7
12/31/2025	6,222	1,166	N/A	1,358	8
12/31/2024	5,488	979	N/A	1,040	8
9/30/2024	5,133	882	596	1,134	N/A
6/30/2024	5,146	865	642	1,221	N/A
3/31/2024	5,013	830	459	1,134	N/A
12/31/2023	4,982	776	376	1,048	N/A
9/30/2023	4,872	738	82	781	N/A
6/30/2023	4,633	682	-131	556	N/A
3/31/2023	4,382	632	-99	502	N/A
12/31/2022	4,187	618	-458	252	N/A
9/30/2022	4,058	616	-277	548	N/A
6/30/2022	4,040	612	-112	674	N/A
3/31/2022	3,991	588	25	773	N/A
12/31/2021	3,875	591	-59	750	N/A
9/30/2021	3,921	620	-55	676	N/A
6/30/2021	3,703	603	-206	551	N/A
3/31/2021	3,592	585	-243	445	N/A
12/31/2020	3,427	564	31	566	N/A
9/30/2020	3,147	532	-6	498	N/A
6/30/2020	3,093	503	89	594	N/A
3/31/2020	3,042	484	-53	596	N/A
12/31/2019	2,992	459	7	599	N/A
9/30/2019	2,821	437	-87	546	N/A
6/30/2019	2,720	409	-31	493	N/A
3/31/2019	2,651	386	124	492	N/A
12/31/2018	2,585	358	118	466	N/A
9/30/2018	2,546	326	245	485	N/A
6/30/2018	2,481	298	N/A	446	N/A
3/31/2018	2,400	281	N/A	349	N/A
12/31/2017	2,330	263	N/A	412	N/A
9/30/2017	2,314	259	N/A	349	N/A
6/30/2017	2,236	236	N/A	423	N/A
3/31/2017	2,181	216	N/A	461	N/A
12/31/2016	2,057	190	N/A	507	N/A
9/30/2016	1,860	162	N/A	478	N/A
6/30/2016	1,801	159	N/A	446	N/A
3/31/2016	1,758	152	N/A	465	N/A
12/31/2015	1,723	145	N/A	390	N/A
9/30/2015	1,771	141	N/A	440	N/A
6/30/2015	1,771	130	N/A	341	N/A
3/31/2015	1,717	127	N/A	293	N/A
12/31/2014	1,691	125	N/A	267	N/A
9/30/2014	1,653	117	N/A	282	N/A
6/30/2014	1,599	122	N/A	260	N/A
3/31/2014	1,577	121	N/A	286	N/A
12/31/2013	1,545	122	N/A	269	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 600529 ( 18.4% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 600529 ( 18.4% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 26.2% per jaar).

Hoge groeiwinsten: De winst van 600529 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 600529 ( 13.6% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 13.9% per jaar).

Hoge groei-inkomsten: De omzet van 600529 ( 13.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 600529 zal naar verwachting over 3 jaar laag zijn ( 13.2 %).

Shandong Pharmaceutical GlassLtd Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 9.7% to CN¥31.77

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Price target decreased by 8.7% to CN¥33.37

Price target decreased to CN¥35.72

Price target decreased to CN¥35.72

Price target decreased to CN¥38.79

Recent updates

Upcoming dividend of CN¥0.30 per share

Shandong Pharmaceutical Glass Co.Ltd to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 16%

Price target decreased by 9.7% to CN¥31.77

Now 21% undervalued after recent price drop

Returns On Capital At Shandong Pharmaceutical GlassLtd (SHSE:600529) Have Hit The Brakes

Dividend of CN¥0.40 announced

Shandong Pharmaceutical Glass Co.Ltd to Report First Half, 2024 Results on Aug 27, 2024

Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)

The Returns At Shandong Pharmaceutical GlassLtd (SHSE:600529) Aren't Growing

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Shandong Pharmaceutical Glass Co.Ltd, Annual General Meeting, May 16, 2024

Shandong Pharmaceutical Glass Co.Ltd to Report Q1, 2024 Results on Apr 23, 2024

Investor sentiment improves as stock rises 16%

Shandong Pharmaceutical Glass Co.Ltd to Report Fiscal Year 2023 Results on Apr 23, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS exceeds analyst expectations

Shandong Pharmaceutical Glass Co.Ltd to Report First Half, 2023 Results on Aug 29, 2023

Price target decreased by 8.7% to CN¥33.37

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Shandong Pharmaceutical Glass Co., Ltd announced that it has received CNY 1.866494692 billion in funding

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Triumph Science & Technology Co.,Ltd (SHSE:600552) cancelled the acquisition of a 11% stake in Shandong Pharmaceutical Glass Co., Ltd (SHSE:600529) from Shandong Luzhong Investment Co., Ltd.

Price target decreased to CN¥35.72

Investor sentiment improved over the past week

Price target decreased to CN¥35.72

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Price target decreased to CN¥38.79

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.26 in 3Q 2020)

Shandong Pharmaceutical Glass Co., Ltd announced that it expects to receive CNY 1.8664947 billion in funding

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.25 (vs CN¥0.21 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.23 in 1Q 2020)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥40.22

Market bids up stock over the past week

New 90-day low: CN¥42.42

Third-quarter earnings released: Revenue misses expectations

Third quarter earnings released

Shandong Pharmaceutical Glass Co., Ltd to Report Q3, 2020 Results on Oct 20, 2020

New 90-day low - CN¥45.11

First half earnings released

New 90-day high - CN¥67.10

Shandong Pharmaceutical Glass Co., Ltd to Report First Half, 2020 Results on Aug 18, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven